Asthma

GSK to Buy Respiratory Drug Developer Aiolos Bio

GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year, Aiolos is a San Francisco, USA and London, UK-based biopharmaceutical company that develops treatments for respiratory diseases.

Topics • Technology

Bioelectronic Medicines: A New Type of Personalization

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

INOSIM GmbH

Predictive Simulation in Pharma Production

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Chemical Market Reporter